These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36971240)

  • 1. Recent progress and structural analyses of domain-selective BET inhibitors.
    Divakaran A; Harki DA; Pomerantz WCK
    Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
    J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
    Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
    J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
    Wahi A; Manchanda N; Jain P; Jadhav HR
    Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomains: a new target class for drug development.
    Cochran AG; Conery AR; Sims RJ
    Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
    Chen J; Tang P; Wang Y; Wang J; Yang C; Li Y; Yang G; Wu F; Zhang J; Ouyang L
    J Med Chem; 2022 Apr; 65(7):5184-5211. PubMed ID: 35324195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.